Renal dysfunction: a novel indicator and potential promoter of cardiovascular risk

ISSN： 1470-2118

Source： Clinical Medicine, Vol.3, Iss.4, 2003-07, pp. : 357-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Asymmetric Dimethylarginine: a Novel Cardiovascular Risk Factor in End-stage Renal Disease

By Alsagaff M Yusuf Thaha M Aminuddin M Yogiarto RM Yogiantoro M Tomino Y

The Journal of International Medical Research, Vol. 40, Iss. 1, 2012-01 ,pp. : 340-349

Field House Publishing

Access to resources Recommend Favorite

Cardiovascular Risk and Endothelial Dysfunction: The Preferential Route for Atherosclerosis

Current Pharmaceutical Biotechnology, Vol. 12, Iss. 9, 2011-09 ,pp. : 1343-1353

Bentham Science Publishers

Access to resources Recommend Favorite

Lipoprotein-associated phospholipase A₂: a novel marker of cardiovascular risk and potential therapeutic target

By Macphee Colin Benson G Martin Shi Yi Zalewski Andrew

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 671-679

Informa Healthcare

Access to resources Recommend Favorite

The therapeutic potential of dopamine modulators on the cardiovascular and renal systems

By Doggrell Sheila A

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 5, 2002-05 ,pp. : 631-644

Informa Healthcare

Access to resources Recommend Favorite

Rofecoxib: increased risk of renal and cardiovascular effects

Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite